Alvocidib in Patients With Previously Treated Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia Arising From Chronic Lymphocytic Leukemia (CLL)

Inclusion Criteria:

Patient must have documentation of histologically confirmed and measurable Chronic Lymphocytic Leukemia (CLL) or Prolymphocytic Leukemia (PLL) arising from CLL;
Patient must have symptomatic and progressive disease;
Patient must have received prior alkylating agent(s) and be fludarabine refractory;
Patient must have the adequate organ functions;
Patient's Eastern Cooperative Oncology Group performance (ECOG) status must be 0-2;

Exclusion Criteria:

Patient with de novo PLL;
Patient with secondary malignancy that will limit survival ≤5 years;
Patient with prior allogenic or autologous bone marrow transplant or peripheral blood stem cell transplant ≤12 months;
Patient receiving an investigational agent or an approved agent for an investigational purpose within last 4 weeks prior to study entry;
Patient with known history of glucose-6-phosphate dehydrogenase deficiency;
Patient with autoimmune hemolytic anemia;
Patient with known Central Nervous System involvement;
Patient with active, uncontrolled serious bacterial, viral or fungal infections

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.